The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri
Abstract
:1. Introduction
2. Materials and Methods
3. Statistical Analyses
4. Results
5. Discussion
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Montazeri, A.; Vahdaninia, M.; Harirchi, I.; Harirchi, A.M.; Sajadian, A.; Khaleghi, F.; Ebrahimi, M.; Haghighat, S.; Jarvandi, S. Breast Cancer in Iran: Need for Greater Women Awareness of Warning Signs and Effective Screening Methods. Asia Pac. Fam. Med. 2008, 7, 6. [Google Scholar] [CrossRef] [PubMed]
- Han, H.; Lee, H.; Kim, M.T.; Kim, K.B. Tailored Lay Health Worker Intervention Improves Breast Cancer Screening Outcomes in Non-Adherent Korean-American Women. Health Educ. Res. 2009, 24, 318–329. [Google Scholar] [CrossRef] [PubMed]
- American Cancer Society. Breast Cancer. American Cancer Society Guidelines for the Early Detection of Cancer. 2011. Available online: https://www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html (accessed on 29 January 2014).
- Arı, A.; Uysal, E.; Özer, H.; Kılınçer, A. Metastatic breast cancer in the uterine cervix. Br. J. Hosp. Med. 2023, 84, 1. [Google Scholar] [CrossRef]
- Parkin, D.M.; Fernandez, L.M. Use of Statistics to Assess the Global Burden of Breast Cancer. Breast J. 2006, 12, 70–80. [Google Scholar] [CrossRef] [PubMed]
- Mayrand, M.; Duarto-Franco, E.; Rodrigues, I.; Walter, S.D.; Hanley, J.; Ferenczy, A.; Ratnam, S.; Coutlée, F.; Franco, E.L. Human Papillomavirus DNA Versus Papanicolaou Screening Tests for Cervical Cancer. N. Engl. J. Med. 2007, 357, 1579–1588. [Google Scholar] [CrossRef]
- Unang, I.; Abasiattai, M.A.; Udoma, J.E. Awareness and Practice of Cervical Smear as A Screening Procedure for Cervical Cancer Among Female Nurses in A Tertiary Hospital in South-South Nigeria. TAF Prev. Med. Bull. 2011, 10, 675–680. [Google Scholar] [CrossRef]
- Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global Cancer Statistics, 2002 CA. Cancer J. Clin. 2005, 55, 74–108. [Google Scholar] [CrossRef]
- Sankaranarayanan, R.; Gaffikin, T.L.; Jacob, M.; Sellors, J.; Robles, S. A Critical Assessment of Screening Methods for Cervical Neoplasia. Int. J. Gynecol. Obstet. 2005, 89, 4–12. [Google Scholar] [CrossRef]
- Aref-Adib, M.; Freeman-Wang, T. Cervical cancer prevention and screening: The role of human papillomavirus testing. Obstet. Gynaecol. 2016, 18, 251–263. [Google Scholar] [CrossRef]
- Lee, R.Y.; Koo, J.Y.; Kim, N.I.; Kim, S.S.; Nam, J.H.; Choi, Y.D. Usefulness of the human papillomavirus DNA chip test as a complementary method for cervical cytology. Cytojournal 2023, 20, 34. [Google Scholar] [CrossRef]
- Curtis, R.E.; Boice, J.D., Jr.; Shriner, D.A.; Hankey, B.F.; Fraumeni, J.F., Jr. Second cancers after adjuvant tamoxifen therapy for breast cancer. J. Natl. Cancer Inst. 1996, 88, 832–834. [Google Scholar] [CrossRef] [PubMed]
- Jordan, V.C.; Murphy, C.S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 1990, 11, 578–610. [Google Scholar] [CrossRef] [PubMed]
- Karimi Zarchi, M.; Behtash, N.; Sekhavat, L.; Dehghan, A. Effects of tamoxifen on the cervix and uterus in women with breast cancer: Experience with Iranian patients and a literature review. Asian Pac. J. Cancer Prev. 2009, 10, 595–598. [Google Scholar] [PubMed]
- Khatcheressian, J.L.; Wolff, A.C.; Smith, T.J.; Grunfeld, E.; Muss, H.B.; Vogel, V.G.; Halberg, F.; Somerfield, M.R.; Davidson, N.E. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol. 2006, 24, 5091–5097. [Google Scholar] [CrossRef] [PubMed]
- Gill, B.L.; Simpson, J.F.; Somlo, G.; McGonigle, K.F.; Wilczynski, S.P. Effects of Tamoxifen on the Cytology of the Uterine Cervix in Breast Cancer Patients. Diagn. Cytopathol. 1998, 19, 417–422. [Google Scholar] [CrossRef]
- Abadi, M.A.; Barakat, R.R.; Saigo, P.E. Effects of tamoxifen on cervicovaginal smears from patients with breast cancer. Acta Cytol. 2000, 44, 141–146. [Google Scholar] [CrossRef] [PubMed]
- Fornander, T.; Rutqvist, L.E.; Wilking, N. Effects of tamoxifen on the female genital tract. Ann. N. Y. Acad. Sci. 1991, 622, 469–476. [Google Scholar] [CrossRef] [PubMed]
- Hwang, J.Y.; Lin, B.Y.; Tang, F.M.; Yu, W.C. Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res. 1992, 52, 6848–6852. [Google Scholar] [PubMed]
- Nonogaki, H.; Fujii, S.; Konishi, I.; Nanbu, Y.; Ozaki, S.; Ishikawa, Y.; Mori, T. Estrogen receptor localization in normal and neoplastic epithelium of the uterine cervix. Cancer 1990, 66, 2620–2627. [Google Scholar] [CrossRef]
- Sankaranarayanan, R.; Chatterji, R.; Shastri, S.S.; Wesley, R.S.; Basu, P.; Mahe, C.; Muwonge, R.; Seigneurin, D.; Somanathan, T.; Roy, C.; et al. Accuracy of Human Papillomavirus Testing in The Primary Screening of Cervical Neoplasia: Results from a Multicentre Study in India. Int. J. Cancer 2004, 112, 341–347. [Google Scholar] [CrossRef]
- Joffroy, C.M.; Buck, M.B.; Stope, M.B.; Popp, S.L.; Pfizenmaier, K.; Knabbe, C. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010, 70, 1314–1322. [Google Scholar] [CrossRef] [PubMed]
- Eells, T.P.; Alpern, H.D.; Grzywacz, C.; MacMillan, R.W.; Olson, J.E. The effect of tamoxifen on cervical squamous maturation in Papanicolaou stained cervical smears of post-menopausal women. Cytopathology 1990, 1, 263–268. [Google Scholar] [CrossRef] [PubMed]
- Mousavi, A.; Karimi Zarchi, M. Isolated cervical metastasis of breast cancer: A case report and literature review. J. Low Genit. Tract Dis. 2007, 11, 276–278. [Google Scholar] [CrossRef] [PubMed]
- Friedrich, M.; Mink, D.; Villena-Heinsen, C.; Woll-Hermann, A.; Schmidt, W. Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998, 80, 221–225. [Google Scholar] [CrossRef] [PubMed]
- Persson, I.; Yuen, J.; Bergkvist, L.; Schairer, C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy—Long-term follow-up of a Swedish cohort. Int. J. Cancer 1996, 67, 327–332. [Google Scholar] [CrossRef]
- Wallach, E.E.; Daniel, Y.; Inbar, M.; Bar-Am, A.; Peyser, M.R.; Lessing, J.B. The effects of tamoxifen treatment on the endometrium. Fertil. Steril. 1996, 65, 1083–1089. [Google Scholar] [CrossRef] [PubMed]
- Bigler, L.R.; Tate Thigpen, J.; Blessing, J.A.; Fiorica, J.; Monk, B.J. Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Int. J. Gynecol. Cancer 2004, 14, 871–874. [Google Scholar] [CrossRef] [PubMed]
- Hsieh, C.J.; Hong, M.K.; Chen, P.C.; Wang, J.H.; Chu, T.Y. Antiestrogen use reduces risk of cervical neoplasia in breast cancer patients: A population-based study. Oncotarget 2017, 8, 29361–29369. [Google Scholar] [CrossRef] [PubMed]
- Dowsett, M.; Cuzick, J.; Ingle, J.; Coates, A.; Forbes, J.; Bliss, J.; Buyse, M.; Buzdar, A.; Colleoni, M.; Coombes, C.; et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 2010, 28, 509–518. [Google Scholar] [CrossRef]
- Chung, S.H.; Wiedmeyer, K.; Shai, A.; Korach, K.S.; Lambert, P.F. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res. 2008, 68, 9928–9934. [Google Scholar] [CrossRef]
- Brake, T.; Lambert, P.F. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc. Natl. Acad. Sci. USA 2005, 102, 2490–2495. [Google Scholar] [CrossRef] [PubMed]
- Chung, S.H.; Franceschi, S.; Lambert, P.F. Estrogen and ERalpha: Culprits in cervical cancer? Trends Endocrinol. Metab. 2010, 21, 504–511. [Google Scholar] [CrossRef] [PubMed]
- Chung, S.H.; Lambert, P.F. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc. Natl. Acad. Sci. USA 2009, 106, 19467–19472. [Google Scholar] [CrossRef] [PubMed]
- Castle, P.E. Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. Int. J. Cancer 2011, 128, 997–998. [Google Scholar] [CrossRef] [PubMed]
- Munger, K. Are selective estrogen receptor modulators (SERMs) a therapeutic option for HPV-associated cervical lesions and cancers? Am. J. Pathol. 2014, 184, 358–361. [Google Scholar] [CrossRef]
- Lan, J.; Chen, L.; Li, Z.; Liu, L.; Zeng, R.; He, Y.; Shen, Y.; Zhang, T.; Ding, Y. Multifunctional Biomimetic Liposomes with Improved Tumor-Targeting for TNBC Treatment by Combination of Chemotherapy, Antiangiogenesis and Immunotherapy. Adv. Healthc. Mater. 2024, 2400046. [Google Scholar] [CrossRef]
Control Cases | Breast Cancer Cases | p-Value | ||
---|---|---|---|---|
Age (mean ± SD) | 47.49 ± 7.95 | 46.73 ± 7.54 | 1 0.530 | |
Gravida (min–max/median) | 0–8/2 | 0–7/2 | 2 0.543 | |
Parity (min–max/median) | 0–6/2 | 0–5/1.5 | 2 0.325 | |
Abortion (min–max/median) | 0–4/0 | 0–2/0 | 2 0.830 | |
D/C (min–max/median) | 0–5/0 | 0–2/0 | 2 0.789 | |
Menopause (n; %) | Yes | 97; 42.2 | 22; 42.3 | 3 0.986 |
No | 133; 57.8 | 30; 57.7 | ||
Co-morbidity (n; %) | Yes | 90; 39.1 | 27; 51.9 | 3 0.091 |
No | 140; 60.9 | 25; 48.1 | ||
Anti-oestrogen (n; %) | Uses | 0; 0 | 51; 98.1 | 4 0.001 ** |
Not Using | 230; 100 | 1; 1.9 | ||
Insulin (n; %) | Uses | 27; 11.7 | 6; 11.5 | 4 1.000 |
Not Using | 203; 88.3 | 46; 88.5 | ||
Steroid (n; %) | Uses | 23; 10.0 | 11; 21.2 | 4 0.046 ** |
Not Using | 207; 90 | 41; 78.8 | ||
Contraception (n; %) | Yes | 68; 29.1 | 13; 25 | 4 0.626 |
No | 162; 70.4 | 39; 75 | ||
Smoking (n; %) | Yes | 96; 41.7 | 21; 4 0.4 | 3 0.858 |
No | 134; 58.3 | 31; 59.6 |
Control Cases | Breast Cancer Cases | p-Value | ||
---|---|---|---|---|
HPV Type Number (n; %) | Single | 75; 32.6 | 14; 26.9 | 4 0.528 |
Multiple | 155; 67.4 | 38; 73.1 | ||
HPV Type (n; %) | Type 16 | 135; 58.7 | 22; 42.3 | 3 0.032 * |
Type 18 | 78; 33.9 | 16; 30.8 | 4 0.786 | |
Type 31 | 30; 13 | 9; 17.3 | 4 0.561 | |
Type 33 | 29; 12.6 | 6; 11.5 | 4 1.000 | |
Type 35 | 11; 4.8 | 1; 1.9 | 5 0.702 | |
Type 39 | 6; 2.6 | 0; 0 | 5 0.597 | |
Type 45 | 27; 11.7 | 6; 11.5 | 4 1.000 | |
Type 52 | 21; 9.1 | 8; 15.4 | 4 0.277 | |
Type 56 | 12; 5.2 | 1; 1.9 | 5 0.474 | |
Type 58 | 12; 5.2 | 3; 5.8 | 5 0.744 | |
Type 59 | 6; 2.6 | 0; 0 | 5 0.597 | |
Type 66 | 2; 0.9 | 0; 0 | 5 1.000 | |
Type 68 | 2; 0.9 | 0; 0 | 5 1.000 | |
Others | 21; 9.1 | 12; 23.1 | 4 0.010 * |
Control Cases | Breast Cancer Cases | p-Value | ||
---|---|---|---|---|
Smear cytology | NILM | 46; 20 | 17; 32.7 | 0.271 |
ASC-US | 43; 18.7 | 6; 11.5 | ||
LGSIL | 72; 31.3 | 16; 30.8 | ||
HGSIL | 41; 17.8 | 8; 15.4 | ||
ASC-H | 16; 7 | 5; 9.6 | ||
AGC-NOS | 11; 4.8 | 0; 0 | ||
AIS | 1; 0.4 | 0; 0 | ||
Colposcopy | NILM | 2; 0.9 | 1; 1.9 | 0.913 |
Chronic cervicitis | 38; 16.5 | 9; 17.3 | ||
LGSIL | 114; 49.6 | 26; 50 | ||
HGSIL | 76; 33 | 16; 30.8 | ||
ECC | Negative | 130; 56.5 | 27; 51.9 | 0.877 |
Chronic cervicitis | 27; 11.7 | 8; 15.4 | ||
HGSIL | 28; 12.2 | 6; 11.5 | ||
LGSIL | 45; 19.6 | 11; 21.2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Cetin, F.; Kayar, İ.; Goc, G.; Birge, Ö. The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri. Medicina 2024, 60, 1268. https://doi.org/10.3390/medicina60081268
Cetin F, Kayar İ, Goc G, Birge Ö. The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri. Medicina. 2024; 60(8):1268. https://doi.org/10.3390/medicina60081268
Chicago/Turabian StyleCetin, Ferhat, İlkan Kayar, Goksu Goc, and Özer Birge. 2024. "The Impact of Tamoxifen Usage in Breast Cancer Patients on the Development of Histopathological Lesions in the Cervix Uteri" Medicina 60, no. 8: 1268. https://doi.org/10.3390/medicina60081268